Akari Therapeutics Receives Notice Related to Delay in 20-F

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
16
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing

NEW YORK and LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that as a result of its inability to timely file its Annual Report on Form 20-F for the year ended December 31, 2017 (the “Annual Report”), on May 17, 2018 it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. Nasdaq Listing Rule 5250(c)(1) requires Nasdaq-listed companies to timely file all periodic reports. Akari intends to regain compliance with Nasdaq’s filing requirements for continued listing.

 As previously disclosed, on May 8, 2018, our former CEO resigned. His resignation followed the results of an investigation conducted, with the assistance of an independent law firm, which revealed that our former CEO incurred personal charges on the Company’s corporate credit cards in violation of Company policy.

The notification from Nasdaq notes that Akari is required to submit a plan to regain compliance with Nasdaq’s filing requirements for continued listing within 60 calendar days of the date of the Nasdaq notification letter. Upon acceptance of the Company’s compliance plan, Nasdaq is permitted to grant an extension of up to 180 calendar days from the Annual Report’s filing due date, or until November 12, 2018, for the Company to regain compliance with Nasdaq’s filing requirements for continued listing.

The notice has no immediate effect on the listing of the Company’s American Depositary Shares on Nasdaq. This announcement is made in compliance with Nasdaq Listing Rule 5810(b) which requires prompt disclosure of receipt of a deficiency notification.

About Akari Therapeutics

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement and the eicosanoid system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari's lead drug candidate Coversin™ is a C5 complement inhibitor currently being evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory activity, Coversin independently and specifically inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin in two conditions, the skin and eye diseases bullous pemphigoid and atopic keratoconjunctivitis, where the dual action of Coversin on both C5 and LTB4 may be beneficial. Akari is also developing other tick derived proteins, including long acting versions.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, an inability or delay in obtaining required regulatory approvals for Coversin and any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as large as expected; risks associated with the putative shareholder class action and SEC requests for information; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F and in our Report on Form 6-K filed with the SEC on October 17, 2017. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:

Peter Vozzo
Westwicke Partners
(443) 213-0505
peter.vozzo@westwicke.com

Media Contact:

Mary-Jane Elliott / Sukaina Virji / Nicholas Brown
Consilium Strategic Communications
+44 (0)20 3709 5700 
Akari@consilium-comms.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 0

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 154

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 24

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 0

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 6

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading

Top 5 Most Recently Viewed Articles

Avanos Medical's Upcoming Earnings: Insights and Risks Ahead

Updated Category News Views 187

Riding the Earnings Wave with Avanos Medical Here we are again, staring down the barrel of another earnings report from Avanos Medical (NYSE:AVNS). It’s set to hit the airwaves on February 24, 2026. Now, I can’t help but think back to previous quarterly reports and the rollercoaster ride those brought. Sometimes it feels like a game of bingo—everyone’s hoping for...

Continue Reading
Agibank's Impressive Financial Growth and Market Strategies

Updated Category News Views 304

Agibank Reports Remarkable Financial Performance Agibank, the innovative digital bank, has showcased strong financial performance, marking substantial growth in its metrics. The bank has effectively combined the efficiency of digital banking with the valuable presence of physical locations, allowing it to flourish in a competitive market. Net Income and Loan Portfolio...

Continue Reading
AllianceBernstein Reports Strong Earnings Growth for AWF

Updated Category News Views 121

AllianceBernstein Global High Income Fund, Inc. Earnings Overview AllianceBernstein Global High Income Fund, Inc. (AWF), a prominent player in the closed-end investment company sector, recently shared its earnings for the first quarter ending June 30. This report highlights the fund's performance, showcasing its growth and resilience amid changing market conditions. Net...

Continue Reading
Experience the Enchantment of Yoobi's Wicked Collection Launch

Updated Category News Views 226

Introducing Yoobi's Wicked Collaboration Unleash your creativity with an enchanting stationery collection inspired by the Wizard of Oz. A Magical New Collection Yoobi, a mission-driven stationery brand, has recently unveiled its latest collaboration with a theme that captures the essence of friendship and individuality inspired by the beloved characters Glinda and Elphaba...

Continue Reading
Deadline Confirmed for NB Bancorp and Provident Merger Process

Updated Category News Views 274

Merger Details Between NB Bancorp and Provident Bancorp NB Bancorp, Inc. (Nasdaq: NBBK), the parent company of Needham Bank, and Provident Bancorp, Inc. (Nasdaq: PVBC), the holding company for BankProv, have announced important details related to their upcoming merger. This strategic merger aims to strengthen both institutions and create greater value for shareholders....

Continue Reading